Healthy men test drug interaction in Early-Stage trial
NCT ID NCT05550636
First seen Jan 10, 2026
Summary
This completed Phase 1 trial looked at whether taking multiple doses of the experimental drug BI 1015550 (nerandomilast) changes how the body processes midazolam, a common sedative. Fifteen healthy men aged 18-55 took part. The goal was to see if BI 1015550 affects a key liver enzyme, which could matter for future patients taking other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1015550 (nerandomilast) and midazolam
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.